Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 268
Filtrar
1.
Nutrients ; 16(17)2024 Sep 02.
Artículo en Inglés | MEDLINE | ID: mdl-39275246

RESUMEN

BACKGROUND: Current treatment for chronic kidney disease (CKD) focuses on improving manifestations and delaying progression. Nutritional approaches play a crucial role in CKD management, and various supplements have become available. Ketoanalogues of amino acids (KAs), calcium citrate, and inulin have been proposed as suitable supplements, yet their widespread use has been limited due to insufficient evidence. This study aimed to generate general guidance statements on the appropriateness of these supplements through a RAND/UCLA consensus process. METHODS: A RAND/UCLA consensus panel was convened to evaluate the appropriateness of these supplements in different clinical scenarios. In this study, we present a subgroup analysis focusing on a panel of eleven clinical nephrologists from among the experts. RESULTS: Supplementation of low-protein diets (LPDs) and very low-protein diets (VLPDs) with KA was considered appropriate to reduce manifestations and delay CKD outcomes, supplementation with calcium citrate is considered appropriate to reduce CKD manifestations, and supplementation with inulin is considered appropriate to delay CKD outcomes and manage comorbidities. CONCLUSIONS: Based on a combination of clinical experience and scientific evidence, the panel reached a consensus that KA supplementation of LPD and VLPD, calcium citrate, and inulin are appropriate in patients with CKD across various scenarios.


Asunto(s)
Aminoácidos , Citrato de Calcio , Consenso , Dieta con Restricción de Proteínas , Suplementos Dietéticos , Inulina , Insuficiencia Renal Crónica , Insuficiencia Renal Crónica/dietoterapia , Humanos , Inulina/administración & dosificación , Aminoácidos/administración & dosificación , Dieta con Restricción de Proteínas/métodos , Citrato de Calcio/administración & dosificación , Citrato de Calcio/uso terapéutico
2.
Nutrients ; 16(17)2024 Sep 09.
Artículo en Inglés | MEDLINE | ID: mdl-39275352

RESUMEN

BACKGROUND/OBJECTIVES: Comprehensive conservative management (CCM) is a viable treatment option for elderly patients with end-stage kidney disease (ESKD). However, it involves a significant change in dietary habits, such as adopting a low-protein diet. Therefore, it is crucial to understand its impact on the patient's quality of life (QoL), particularly when compared to hemodialysis (HD). The study aims to evaluate the differences in the QoL between patients undergoing CCM and HD. METHODS: The study included 50 patients over 75 with ESKD, with 25 patients in the CCM group and 25 in the HD group. The CCM group followed a personalized low-protein diet, while the HD group did not have protein restrictions. Various parameters were assessed, including demographic data, urine output, blood tests, comorbidity index, Visual Analog Scale (VAS), and hospitalization. The SF-12 questionnaire assessed the QoL, and the Physical Composite Score (PCS) and Mental Composite Score (MCS) were calculated. RESULTS: The study revealed no age and comorbidity index differences between CCM and HD patients. In contrast, CCM patients reported significantly better physical and mental well-being than HD patients. In univariate analysis, CCM (B 0.24, p = 0.001), protein intake (B -0.004, p = 0.008), hospitalization (B -0.18, p = 0.024), urine output (B 0.25, p = 0.001), and VAS (B -0.26, p < 0.001) influenced the PCS. At the same time, only the type of treatment (B = 0.15, p = 0.048), urine output (B 0.18, p = 0.02), and VAS (B -0.14, p = 0.048) influence the MCS. In contrast, in multivariate analysis, only CCM contributed to an improved PCS (B 0.19, p = 0.003) and MCS (B 0.16, p = 0.03), while a higher VAS worsened the PCS (B -0.24, p < 0.001) and MCS (B -0.157, p = 0.0024). CONCLUSIONS: In elderly patients with similar basal conditions, health-related QoL perception is better in CCM than in HD patients.


Asunto(s)
Tratamiento Conservador , Fallo Renal Crónico , Calidad de Vida , Diálisis Renal , Humanos , Femenino , Anciano , Masculino , Estudios de Casos y Controles , Tratamiento Conservador/métodos , Anciano de 80 o más Años , Fallo Renal Crónico/terapia , Fallo Renal Crónico/psicología , Dieta con Restricción de Proteínas/métodos , Encuestas y Cuestionarios
3.
Eur J Clin Nutr ; 78(9): 737-747, 2024 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-38961262

RESUMEN

Low-protein diet (LPD) is the core of dietary and nutritional therapy for non-dialysis chronic kidney disease (CKD) patients. In addition, physical exercise could prevent and treat various illnesses and chronic diseases. The objective of the study was to search for and appraise evidence on the effect of additional physical exercise on patients' nutritional status and indicators of disease progression when compared with the LPD alone. PubMed Central, Embase, Cochrane, and Web of Knowledge for randomized controlled trials (published between January 1, 1956 and May 17, 2023) were searched. A total of 8698 identified studies, 9 were eligible and were included in our analysis (N = 250 participants). Compared with the LPD alone, additional physical exercise reduced serum creatinine by a mean of -0.21 mg/dL (95% CI -0.39 to -0.03) in CKD patients. Similarly, blood pressure decreased after physical exercise, with systolic blood pressure decreasing by -7.05 mm Hg (95% CI -13.13 to -0.96) and diastolic blood pressure decreasing by -5.31 mm Hg (95% CI -7.99 to -2.62). Subgroup analyses revealed that resistance exercise (RE) was effective in decreasing estimated glomerular filtration rate (eGFR) of -1.71 mL/min per 1.73 m² (95% CI -3.29 to -0.14). In addition, the VO2peak increasing by 2.41 mL/kg/min (95% CI 0.13 to 4.70) when physical exercise was continued for 24 weeks. The above results suggest that the LPD with additional physical exercise care is more beneficial for patients with CKD.


Asunto(s)
Dieta con Restricción de Proteínas , Progresión de la Enfermedad , Ejercicio Físico , Estado Nutricional , Insuficiencia Renal Crónica , Humanos , Insuficiencia Renal Crónica/terapia , Insuficiencia Renal Crónica/dietoterapia , Dieta con Restricción de Proteínas/métodos , Ejercicio Físico/fisiología , Presión Sanguínea
4.
Nutrients ; 16(14)2024 Jul 11.
Artículo en Inglés | MEDLINE | ID: mdl-39064671

RESUMEN

Low-protein diets (LPDs) seem to improve metabolic complications of advanced CKD, thus postponing kidney replacement therapy (KRT) initiation. However, the nutritional safety of LPDs remains debatable in patients with diabetic kidney disease (DKD), especially in the elderly. This is a sub-analysis of a prospective unicentric interventional study which assessed the effects of LPD in patients with advanced DKD, focusing on the feasibility and safety of LPD in elderly patients. Ninety-two patients with DKD and stable CKD stage 4+, proteinuria >3 g/g creatininuria, good nutritional status, with confirmed compliance to protein restriction, were enrolled and received LPD (0.6 g mixed proteins/kg-day) supplemented with ketoanalogues of essential amino acids for 12 months. Of the total group, 42% were elderly with a median eGFR 12.6 mL/min and a median proteinuria 5.14 g/g creatininuria. In elderly patients, proteinuria decreased by 70% compared to baseline. The rate of kidney function decline was 0.1 versus 0.5 mL/min-month before enrolment. Vascular events occurred in 15% of cases, not related to nutritional intervention, but to the severity of CKD and higher MAP. LPDs seem to be safe and effective in postponing KRT in elderly patients with advanced DKD while preserving the nutritional status.


Asunto(s)
Nefropatías Diabéticas , Dieta con Restricción de Proteínas , Proteinuria , Humanos , Dieta con Restricción de Proteínas/métodos , Anciano , Masculino , Femenino , Nefropatías Diabéticas/dietoterapia , Estudios Prospectivos , Proteinuria/dietoterapia , Persona de Mediana Edad , Anciano de 80 o más Años , Tasa de Filtración Glomerular , Resultado del Tratamiento , Estado Nutricional , Insuficiencia Renal Crónica/dietoterapia , Aminoácidos Esenciales/administración & dosificación
5.
Nutr J ; 23(1): 75, 2024 Jul 15.
Artículo en Inglés | MEDLINE | ID: mdl-39004744

RESUMEN

OBJECTIVE: An increasing number of studies shown that inadequate energy intake causes an increase in adverse incidents in chronic kidney disease (CKD) patients on low-protein diets (LPD). The study aimed to investigate the relationship between energy intake and cardiovascular mortality in CKD patients on a LPD. METHODS: This was a cross-sectional study, a total of 4264 CKD patients were enrolled from the NHANES database between 2009 and 2018. Restricted cubic spline plots and Cox regression analysis were used to analyze the association between energy intake and cardiovascular mortality in CKD patients on a LPD. Additionally, a nomogram was constructed to estimate cardiovascular survival in CKD patients on a LPD. RESULTS: Among CKD patients on a LPD in the United States, 90.05% had an energy intake of less than 25 kcal/kg/day, compared to 36.94% in CKD patients on a non-LPD. Energy intake and cardiovascular mortality showed a linear relationship in CKD patients on a LPD, while a 'U-shaped' relationship was observed in CKD patients on a non-LPD. Multifactorial Cox regression models revealed that for Per-standard deviation (Per-SD) decrement in energy intake, the risk of cardiovascular mortality increased by 41% (HR: 1.41, 95% CI: 1.12, 1.77; P = 0.004) in CKD patients on a LPD. The concordance index of the nomogram was 0.79 (95% CI, 0.75, 0.83). CONCLUSION: CKD patients, especially those on a LPD, have significantly inadequate energy intake. Lower energy intake is associated with higher cardiovascular mortality in CKD patients on a LPD.


Asunto(s)
Enfermedades Cardiovasculares , Dieta con Restricción de Proteínas , Ingestión de Energía , Encuestas Nutricionales , Insuficiencia Renal Crónica , Humanos , Masculino , Insuficiencia Renal Crónica/mortalidad , Insuficiencia Renal Crónica/complicaciones , Femenino , Enfermedades Cardiovasculares/mortalidad , Persona de Mediana Edad , Estudios Transversales , Encuestas Nutricionales/métodos , Encuestas Nutricionales/estadística & datos numéricos , Dieta con Restricción de Proteínas/métodos , Anciano , Estados Unidos/epidemiología , Adulto , Factores de Riesgo , Modelos de Riesgos Proporcionales
6.
Nutrients ; 16(11)2024 May 29.
Artículo en Inglés | MEDLINE | ID: mdl-38892620

RESUMEN

Low protein diet (LPD) seems beneficial in ameliorating the complications of chronic kidney disease (CKD), in reducing proteinuria and the decline in kidney function, thus postponing the need for kidney replacement therapy (KRT). However, this type of intervention was less investigated in diabetic kidney disease (DKD). This is a single-center, prospective, interventional study that aims to assess the efficacy of reducing proteinuria and the rate of decline in the estimated glomerular filtration rate (eGFR). Patients with advanced DKD (stable proteinuria > 3 g/g and eGFR < 30 mL/min) with a good nutritional status and accepting a LPD were evaluated for inclusion. Ninety-two of the 452 screened patients (66% males, median age 61 years, proteinuria 4.8 g/g creatininuria, eGFR 11.7 mL/min/1.73 m2) completed the study. Intervention consisted of LPD supplemented with ketoanalogues of essential amino acids (KA) along with conventional nephroprotective therapy. Efficacy parameters were the variation in proteinuria and in eGFR from baseline to the end of the study. Proteinuria decreased 3-fold, and the rate of decline in eGFR decreased 5-fold in the intervention phase. No patient initiated KRT or died. LPD supplemented with KA seems effective in safely postponing KRT by reducing proteinuria and the decline in kidney function in advanced DKD.


Asunto(s)
Nefropatías Diabéticas , Dieta con Restricción de Proteínas , Tasa de Filtración Glomerular , Proteinuria , Humanos , Masculino , Proteinuria/dietoterapia , Persona de Mediana Edad , Dieta con Restricción de Proteínas/métodos , Nefropatías Diabéticas/dietoterapia , Nefropatías Diabéticas/fisiopatología , Femenino , Estudios Prospectivos , Anciano , Aminoácidos Esenciales/administración & dosificación , Resultado del Tratamiento
7.
Nutrients ; 16(10)2024 May 16.
Artículo en Inglés | MEDLINE | ID: mdl-38794736

RESUMEN

INTRODUCTION: Chronic kidney disease is a degenerative and increasingly prevalent condition that includes metabolic abnormalities and is associated with a higher risk of sarcopenia. The conservative approach points primarily to controlling metabolic issues and reducing the risk of malnutrition and sarcopenia, slowing the progression of kidney disease. The present study aims to evaluate the effect of a low-protein diet on malnutrition and sarcopenia. METHODS: A total of 45 patients (33 male and 12 female) aged over 70 with chronic kidney disease stage 4-5 in conservative management were considered. All patients had a dietary assessment and prescription of personalized low-protein dietary plans (≤0.6 g protein/kg) and a follow-up control between 4 and 6 months. In preliminary and follow-up evaluations, anthropometric data, blood examinations, body composition results, muscle strength, physical performance, and a 3-day food diary were collected. RESULTS: In the follow-up period, a significant weight loss (p = 0.001) and a decrease in body mass index (p = 0.002) were recorded. Food diaries revealed a significant reduction in protein, sodium, potassium, and phosphorus intake (p < 0.001), with a significant reduction in urea (p < 0.001) and proteinuria (p = 0.01) without any impact on lean mass (p = 0.66). Considerable variations in adherence between food diaries and the prescribed diet were also noted. CONCLUSIONS: Providing a personalized low-protein diet led to significant benefits in a short period without worsening the patient's nutritional status.


Asunto(s)
Dieta con Restricción de Proteínas , Insuficiencia Renal Crónica , Sarcopenia , Humanos , Masculino , Femenino , Insuficiencia Renal Crónica/dietoterapia , Insuficiencia Renal Crónica/terapia , Anciano , Sarcopenia/dietoterapia , Dieta con Restricción de Proteínas/métodos , Anciano de 80 o más Años , Tratamiento Conservador/métodos , Índice de Masa Corporal , Composición Corporal , Estado Nutricional , Desnutrición/dietoterapia , Fuerza Muscular , Pérdida de Peso
8.
Br J Hosp Med (Lond) ; 85(5): 1-5, 2024 May 30.
Artículo en Inglés | MEDLINE | ID: mdl-38815966

RESUMEN

A low-protein diet (LPD) has become an important way to delay the progression of chronic kidney disease (CKD) and to delay the need for dialysis. A review of the literature reveals the low-protein diet's influence on the course of chronic kidney disease. An artificial low-protein food, wheat starch, for example, can not only increase the high-quality protein intake ratio, but can ensure adequate energy intake on a low-protein diet while meeting the nutritional needs of the body, effectively reducing the burden on the damaged kidneys. The purpose of this review is to provide a reference for the clinical implementation of diet and nutrition therapy in patients with chronic kidney disease.


Asunto(s)
Dieta con Restricción de Proteínas , Progresión de la Enfermedad , Insuficiencia Renal Crónica , Humanos , Dieta con Restricción de Proteínas/métodos , Insuficiencia Renal Crónica/dietoterapia , Insuficiencia Renal Crónica/terapia , Proteínas en la Dieta/administración & dosificación
9.
Eur J Clin Nutr ; 78(6): 544-547, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38383708

RESUMEN

The New Nordic Renal Diet (NNRD) is a meal pattern reduced in phosphorus, protein, and sodium for patients with moderate chronic kidney disease. The NNRD showed improvements in metabolic, and physiological outcomes after 26-weeks intervention. In the original study, participants were randomized to NNRD (n = 30), or control (habitual diet) (n = 30). The aim of this study was to explore adherence to the NNRD 3 months after cessation of intervention (follow-up). Fifty-seven participants completed the follow-up visit, which consisted of fasting blood samples and 24 h urine samples. At follow-up, there was no longer a significant reduction in 24 h urine phosphorus excretion in the NNRD group. From intervention to follow-up, 24 h urine phosphorus increased by 63 mg in the NNRD group, vs. -24.1 mg in the control group, between-group difference 87.1 mg (-10.1, 184.3, p = 0.08). Our findings show that more active intervention is needed to support adherence and maintain beneficial effects of the NNRD.


Asunto(s)
Cooperación del Paciente , Insuficiencia Renal Crónica , Humanos , Insuficiencia Renal Crónica/dietoterapia , Masculino , Femenino , Persona de Mediana Edad , Anciano , Fósforo Dietético/administración & dosificación , Dieta Hiposódica/métodos , Adulto , Fósforo/sangre , Fósforo/orina , Estudios de Seguimiento , Proteínas en la Dieta/administración & dosificación , Dieta con Restricción de Proteínas/métodos
10.
Semin Nephrol ; 43(2): 151402, 2023 03.
Artículo en Inglés | MEDLINE | ID: mdl-37536057

RESUMEN

Nutritional therapy is a cornerstone of the clinical management of chronic kidney disease (CKD). Nevertheless, randomized controlled trials often have failed to show a relevant benefit of low-protein diets in nonselected CKD populations in terms of slowing the progression of kidney disease and need for dialysis. The more the target population is selected, the less the results can be generalizable to implement in clinical practice. On the contrary, observational studies, especially if performed with patient-centered, flexible approaches, point toward an extensive implementation of dietary protein restriction in different and unselected CKD populations. The observational evidence cannot be disregarded anymore. The most recent guidelines advise implementing low-protein diets or even very-low-protein diets in all CKD patients as early as stage 3. However, the lack of data from large randomized controlled trials on unselected CKD populations as well as on specific subpopulations, such as diabetic or obese patients, which nowadays comprise the majority of CKD subjects, reduces the generalizability of the recommendations. For some patient populations, such as those encompassing very old, nephrotic, or pregnant patients, the literature is even more limited because of the lower prevalence of these conditions and diffused prejudices against reducing protein intake. This pragmatic review discusses the need for integrating information derived from randomized trials with evidence derived from observational studies to guide feasible strategies for more successful implementation of low-protein diets in the treatment of all segments of the CKD population.


Asunto(s)
Dieta con Restricción de Proteínas , Insuficiencia Renal Crónica , Embarazo , Femenino , Humanos , Dieta con Restricción de Proteínas/efectos adversos , Dieta con Restricción de Proteínas/métodos , Ensayos Clínicos Controlados Aleatorios como Asunto , Insuficiencia Renal Crónica/metabolismo , Diálisis Renal , Obesidad
11.
Int J Mol Sci ; 23(4)2022 Feb 17.
Artículo en Inglés | MEDLINE | ID: mdl-35216344

RESUMEN

Phenylketonuria (PKU) is a rare autosomal recessive inborn error of metabolism where the mainstay of treatment is a Phe restricted diet consisting of a combination of limited amounts of natural protein with supplementation of Phe-free or low-Phe protein substitutes and special low protein foods. Suboptimal outcomes may be related to the different absorption kinetics of free AAs, which have lower biological efficacy than natural proteins. Physiomimic TechnologyTM is a technology engineered to prolong AA (AA-PT) release allowing physiological absorption and masking the odor and taste of free AAs. The aim of these studies was to assess the impact of AA-PT formulation on selected functional and metabolic parameters both in acute and long-term experimental studies. Adult rats in fasting conditions were randomized in different groups and treated by oral gavage. Acute AA-PT administration resulted in significantly lower BUN at 90 min versus baseline. Both BUN and glycemia were modulated in the same direction as intact casein protein. Long-term treatment with AA-PT significantly reduces the protein expression of the muscle degradation marker Bnip3L (-46%) while significantly increasing the proliferation of market myostatin (+58%). Animals dosed for 15 days with AA-PT had significantly stronger grip strength (+30%) versus baseline. In conclusion, the results suggest that the AA-PT formulation may have beneficial effects on both AA oxidation and catabolism with a direct impact on muscle as well as on other metabolic pathways.


Asunto(s)
Aminoácidos/metabolismo , Aminoácidos/farmacología , Fenilcetonurias/tratamiento farmacológico , Fenilcetonurias/metabolismo , Animales , Biomarcadores/metabolismo , Caseínas/metabolismo , Dieta con Restricción de Proteínas/métodos , Masculino , Proteínas de la Membrana/metabolismo , Miostatina/metabolismo , Ratas , Ratas Wistar
12.
Nutrients ; 13(12)2021 Dec 06.
Artículo en Inglés | MEDLINE | ID: mdl-34959922

RESUMEN

The recent guidelines on nutritional management of chronic kidney disease (CKD) advise a reduction in protein intake as early as CKD stage 3, regardless of age, to slow kidney function impairment. However, since elderly patients are usually considered as having a spontaneously reduced protein intake, nutritional interventions to reduce protein intake are often considered futile. This study aimed to assess the baseline protein intake of elderly CKD patients referred for nephrology care, and explore the need for dietary evaluations, focusing on the current recommendations for protein restriction in CKD. This is an observational study of CKD patients followed in the unit dedicated to advanced CKD patients in Le Mans, France. Patients with stages 3 to 5 not on dialysis were included. All patients were evaluated by an expert dietician to assess their baseline protein intake, whenever possible on the basis of a 7-days diet journal; when this was not available, dietary recall or analysis of delivered meals was employed. Demographic characteristics, underlying kidney disease, Charlson Comorbidity Index (CCI), Malnutrition-Inflammation Score (MIS), Subjective Global Assessment (SGA) and clinical and laboratory data were recorded. Between 15 November 2017 and 31 December 2020, 436 patients were evaluated in the unit. Their age distribution was as follows: "young": <60 (n = 62), "young-old": 60-69 (n = 74), "old": 70-79 (n = 108), "old-old": 80-89 (n = 140) and "oldest-old": ≥90 (n = 54). The prevalence of vascular nephropathies was higher in patients older than 70 years compared to younger ones, as did CCI and MIS (p < 0.001). Moderate nutritional impairment (SGA: B) was higher in elderly patients, reaching 53.7% at ≥90, while less than 3% of patients in the overall cohort were classified as SGA C (p < 0.001). The median protein intake was higher than the recommended one of 0.8 g/kg/day in all age groups; it was 1.2 g/kg/day in younger patients and 1.0 thereafter (p < 0.001). Patient survival depended significantly on age (p < 0.001) but not on baseline protein intake (p = 0.63), and younger patients were more likely to start dialysis during follow-up (p < 0.001). Over half of the patients, including the old-old and oldest-old, were still on follow-up two years after referral and it was found that survival was only significantly associated with age and comorbidity and was not affected by baseline protein intake. Our study shows that most elderly patients, including old-old and extremely old CKD patients, are spontaneously on diets whose protein content is higher than recommended, and indicates there is a need for nutritional care for this population.


Asunto(s)
Dieta con Restricción de Proteínas/métodos , Proteínas en la Dieta/administración & dosificación , Desnutrición/prevención & control , Terapia Nutricional/métodos , Insuficiencia Renal Crónica/dietoterapia , Factores de Edad , Anciano , Anciano de 80 o más Años , Estudios de Cohortes , Comorbilidad , Femenino , Estudios de Seguimiento , Francia/epidemiología , Humanos , Masculino , Desnutrición/etiología , Persona de Mediana Edad , Gravedad del Paciente , Insuficiencia Renal Crónica/epidemiología , Insuficiencia Renal Crónica/mortalidad , Tasa de Supervivencia
13.
Nutrients ; 13(11)2021 Oct 28.
Artículo en Inglés | MEDLINE | ID: mdl-34836117

RESUMEN

Children spend a substantial part of their childhood in school, so provision of dietary care and inclusion of children with phenylketonuria (PKU) in this setting is essential. There are no reports describing the dietary support children with PKU receive whilst at school. The aim of this cross-sectional study was to explore the experiences of the dietary management of children with PKU in schools across the UK. Data was collected using an online survey completed by parents/caregivers of children with PKU. Of 159 questionnaire responses, 92% (n = 146) of children attended state school, 6% (n = 10) private school and 2% (n = 3) other. Fourteen per cent (n = 21/154) were at nursery/preschool, 51% (n = 79/154) primary and 35% (n = 54/154) secondary school. Sixty-one per cent (n = 97/159) said their child did not have school meals, with some catering services refusing to provide suitable food and some parents distrusting the school meals service. Sixty-one per cent of children had an individual health care plan (IHCP) (n = 95/155). Children were commonly unsupervised at lunchtime (40%, n = 63/159), with snacks (46%, n = 71/155) and protein substitute (30%, n = 47/157), with significantly less supervision in secondary than primary school (p < 0.001). An IHCP was significantly associated with improved supervision of food and protein substitute administration (p < 0.01), and better communication between parents/caregivers and the school team (p < 0.05). Children commonly accessed non-permitted foods in school. Therefore, parents/caregivers described important issues concerning the school provision of low phenylalanine food and protein substitute. Every child should have an IHCP which details their dietary needs and how these will be met safely and discreetly. It is imperative that children with PKU are supported in school.


Asunto(s)
Dieta con Restricción de Proteínas/psicología , Servicios de Alimentación/organización & administración , Padres/psicología , Fenilcetonurias/dietoterapia , Servicios de Salud Escolar/organización & administración , Adolescente , Niño , Preescolar , Estudios Transversales , Dieta con Restricción de Proteínas/métodos , Femenino , Humanos , Masculino , Instituciones Académicas , Encuestas y Cuestionarios , Reino Unido
14.
Nutrients ; 13(10)2021 Oct 17.
Artículo en Inglés | MEDLINE | ID: mdl-34684639

RESUMEN

Obesity and associated insulin resistance (Ins-R) have been identified as important risk factors for esophageal adenocarcinoma development. Elevated calories and protein consumption are also associated with Ins-R and glucose intolerance. We investigated the effect of a 24-month moderate calorie and protein restriction program on overweight or obese patients affected by Barrett's esophagus (BE), as no similar dietary approach has been attempted to date in this disease context. Anthropometric parameters, levels of serum analytes related to obesity and Ins-R, and the esophageal insulin/IGF-1 signaling pathway were analyzed. This study is registered with ClinicalTrials.gov, number NCT03813381. Insulin, C-peptide, IGF-1, IGF-binding protein 3 (IGFBP3), adipokines, and esophageal expression of the main proteins involved in insulin/IGF-1 signal transduction were quantified using Luminex-XMAP® technology in 46 patients who followed the restriction program (IA) and in 54 controls (CA). Body mass index and waist circumference significantly decreased in 76.1% of IA and 35.2% of CA. IGF-1 levels were reduced in 71.7% of IA and 51.8% of CA. The simultaneous reduction of glycaemia, IGF-1, the IGF-1/IGFBP3 ratio, and the improvement in weight loss-dependent insulin sensitivity, were associated with the downregulation of the insulin/IGF-1 signal on BE tissue. The proposed intervention program was an effective approach to counteract obesity-associated cancer risk factors. The improvement in metabolic condition resulted in a downregulation of the ERK-mediated mitogenic signal in 43.5% of patients, probably affecting the molecular mechanism driving adenocarcinoma development in BE lesions.


Asunto(s)
Esófago de Barrett/dietoterapia , Restricción Calórica/métodos , Dieta con Restricción de Proteínas/métodos , Factor I del Crecimiento Similar a la Insulina/metabolismo , Insulina/metabolismo , Adenocarcinoma/etiología , Adenocarcinoma/prevención & control , Anciano , Esófago de Barrett/complicaciones , Esófago de Barrett/metabolismo , Índice de Masa Corporal , Regulación hacia Abajo , Neoplasias Esofágicas/etiología , Neoplasias Esofágicas/prevención & control , Femenino , Humanos , Resistencia a la Insulina , Sistema de Señalización de MAP Quinasas/fisiología , Masculino , Persona de Mediana Edad , Obesidad/complicaciones , Obesidad/dietoterapia , Obesidad/metabolismo , Transducción de Señal/fisiología , Resultado del Tratamiento , Circunferencia de la Cintura , Pérdida de Peso
15.
Sci Rep ; 11(1): 19184, 2021 09 28.
Artículo en Inglés | MEDLINE | ID: mdl-34584168

RESUMEN

Despite decades of use of low protein diets (LPD) in the management of chronic kidney disease (CKD), their mechanisms of action are unclear. A reduced production of uremic toxins could contribute to the benefits of LPDs. Aromatic amino-acids (AA) are precursors of major uremic toxins such as p-cresyl sulfate (PCS) and indoxyl sulfate (IS). We hypothesize that a low aromatic amino acid diet (LA-AAD, namely a low intake of tyrosine, tryptophan and phenylalanine) while being normoproteic, could be as effective as a LPD, through the decreased production of uremic toxins. Kidney failure was chemically induced in mice with a diet containing 0.25% (w/w) of adenine. Mice received three different diets for six weeks: normoproteic diet (NPD: 14.7% proteins, aromatic AAs 0.019%), LPD (5% proteins, aromatic AAs 0.007%) and LA-AAD (14% proteins, aromatic AAs 0.007%). Both LPD and LA-AAD significantly reduced proteinuria, kidney fibrosis and inflammation. While LPD only slightly decreased plasma free PCS and free IS compared to NPD; free fractions of both compounds were significantly decreased by LA-AAD. These results suggest that a LA-AAD confers similar benefits of a LPD in delaying the progression of CKD through a reduction in some key uremic toxins production (such as PCS and IS), with a lower risk of malnutrition.


Asunto(s)
Aminoácidos Aromáticos/efectos adversos , Dieta con Restricción de Proteínas/métodos , Riñón/patología , Desnutrición/prevención & control , Insuficiencia Renal Crónica/dietoterapia , Animales , Dieta con Restricción de Proteínas/efectos adversos , Modelos Animales de Enfermedad , Fibrosis , Humanos , Masculino , Desnutrición/etiología , Ratones , Insuficiencia Renal Crónica/patología , Tóxinas Urémicas/metabolismo
16.
Nutrients ; 13(9)2021 Sep 06.
Artículo en Inglés | MEDLINE | ID: mdl-34578995

RESUMEN

Blood phenylalanine (Phe) is used as the primary marker to evaluate metabolic control. Our study aimed to describe the metabolic control of patients with phenylketonuria (PKU) comparing three different treatment recommendations (European guidelines/US guidelines/Portuguese consensus). This was a retrospective, observational, single centre study in patients with PKU collecting data on blood Phe levels from 2017. Nutritional intake data and sapropterin (BH4) prescription were collected at the last appointment of 2017. The final sample studied included 87 patients (48% females) [13 hyperphenylalaninemia; 47 mild PKU; 27 classical PKU] with a median age of 18 y (range: 1-36 y). The median number of blood Phe measurements for patients was 21 (range: 6-89). In patients aged < 12 y, the median blood Phe level was 300 µmol/L (range 168-480) and 474 µmol/L (range 156-1194) for patients ≥ 12 y. Overall, a median of 83% of blood Phe levels were within the European PKU guidelines target range. In patients aged ≥ 12 years, there was a higher median % of blood Phe levels within the European PKU guidelines target range (≥12 y: 84% vs. <12 y: 56%). In children < 12 y with classical PKU (n = 2), only 34% of blood Phe levels were within target range for all 3 guidelines and 49% with mild PKU (n = 11). Girls had better control than boys (89% vs. 66% median Phe levels within European Guidelines). Although it is clear that 50% or more patients were unable to achieve acceptable metabolic control on current treatment options, a globally agreed upper Phe target associated with optimal outcomes for age groups is necessary. More studies need to examine how clinics with dissimilar resources, different therapeutic Phe targets and frequency of monitoring relate to metabolic control.


Asunto(s)
Biopterinas/análogos & derivados , Dieta con Restricción de Proteínas/métodos , Fenilalanina/sangre , Fenilcetonurias/sangre , Fenilcetonurias/terapia , Adolescente , Adulto , Biomarcadores/sangre , Biopterinas/uso terapéutico , Niño , Preescolar , Ingestión de Alimentos , Femenino , Humanos , Lactante , Masculino , Portugal , Guías de Práctica Clínica como Asunto , Estándares de Referencia , Valores de Referencia , Estudios Retrospectivos , Resultado del Tratamiento , Adulto Joven
17.
Nutrients ; 13(4)2021 Apr 18.
Artículo en Inglés | MEDLINE | ID: mdl-33919635

RESUMEN

Prescribing a low-protein diet (LPD) is part of the standard management of patients in advanced stages of chronic kidney disease (CKD). However, studies on the quality of life (QoL) of patients on LPDs are lacking, and the impact these diets have on their QoL is often given as a reason for not prescribing one. We, therefore, decided to assess the QoL in a cohort of CKD stage 3-5 patients followed up by a multiple-choice diet approach in an outpatient nephrology clinic in France. To do so, we used the short version of the World Health Organization's quality of life questionnaire and compared the results with a historical cohort of Italian patients. We enrolled 153 patients, managed with tailored protein restriction in Le Mans, and compared them with 128 patients on similar diets who had been followed in Turin (Italy). We found there were no significant differences in terms of age (median 73 vs. 74 years, respectively), gender, CKD stage, and comorbidities (Charlson's Comorbidity Index 7 vs. 6). French patients displayed a greater body mass index (29.0 vs. 25.4, p < 0.001) and prevalence of obesity (41.2 vs. 15.0%, p < 0.001). Baseline protein intake was over the target in France (1.2 g/kg of real body weight/day). In both cohorts, the burden of comorbidities was associated with poorer physical health perception while kidney function was inversely correlated to satisfaction with social life, independently of the type of diet. Our study suggests that the type of LPD they follow does not influence QoL in CKD patients and that a personalized approach towards protein restriction is feasible, even in elderly patients.


Asunto(s)
Dieta con Restricción de Proteínas/psicología , Calidad de Vida/psicología , Insuficiencia Renal Crónica/dietoterapia , Insuficiencia Renal Crónica/psicología , Anciano , Anciano de 80 o más Años , Índice de Masa Corporal , Estudios de Cohortes , Comorbilidad , Comparación Transcultural , Dieta con Restricción de Proteínas/métodos , Femenino , Francia/epidemiología , Humanos , Italia/epidemiología , Masculino , Persona de Mediana Edad , Obesidad/complicaciones , Obesidad/epidemiología , Obesidad/psicología , Satisfacción del Paciente , Prevalencia , Estudios Prospectivos , Insuficiencia Renal Crónica/complicaciones , Encuestas y Cuestionarios , Resultado del Tratamiento
18.
Nutrients ; 13(3)2021 Mar 16.
Artículo en Inglés | MEDLINE | ID: mdl-33809492

RESUMEN

Chronic kidney disease (CKD) is a global public health burden, needing comprehensive management for preventing and delaying the progression to advanced CKD. The role of nutritional therapy as a strategy to slow CKD progression and uremia has been recommended for more than a century. Although a consistent body of evidence suggest a benefit of protein restriction therapy, patients' adherence and compliance have to be considered when prescribing nutritional therapy in advanced CKD patients. Therefore, these prescriptions need to be individualized since some patients may prefer to enjoy their food without restriction, despite knowing the potential importance of dietary therapy in reducing uremic manifestations, maintaining protein-energy status.


Asunto(s)
Dieta con Restricción de Proteínas , Insuficiencia Renal Crónica/dietoterapia , Dieta con Restricción de Proteínas/métodos , Proteínas en la Dieta/administración & dosificación , Humanos
19.
Nutrients ; 13(2)2021 Jan 30.
Artículo en Inglés | MEDLINE | ID: mdl-33573238

RESUMEN

There has been a growing interest in the gastrointestinal system and its significance for autism spectrum disorder (ASD), including the significance of adopting a gluten-free and casein-free (GFCF) diet. The objective was to investigate beneficial and safety of a GFCF diet among children with a diagnosis of ASD. We performed a systematic literature search in Medline, Embase, Cinahl, and the Cochrane Library up to January 2020 for existing systematic reviews and individual randomized controlled trials (RCTs). Studies were included if they investigated a GFCF diet compared to a regular diet in children aged 3 to 17 years diagnosed with ASD, with or without comorbidities. The quality of the identified existing reviews was assessed using A Measurement Tool to Assess Systematic Reviews (AMSTAR). The risk of bias in RCTs was assessed using the Cochrane Risk of Bias Tool, and overall quality of evidence was evaluated using Grades of Recommendation, Assessment, Development, and Evaluation (GRADE). We identified six relevant RCTs, which included 143 participants. The results from a random effect model showed no effect of a GFCF diet on clinician-reported autism core symptoms (standardized mean difference (SMD) -0.31 (95% Cl. -0.89, 0.27)), parent-reported functional level (mean difference (MD) 0.61 (95% Cl -5.92, 7.14)) or behavioral difficulties (MD 0.80 (95% Cl -6.56, 10.16)). On the contrary, a GFCF diet might trigger gastrointestinal adverse effects (relative risk (RR) 2.33 (95% Cl 0.69, 7.90)). The quality of evidence ranged from low to very low due to serious risk of bias, serious risk of inconsistency, and serious risk of imprecision. Clinical implications of the present findings may be careful consideration of introducing a GFCF diet to children with ASD. However, the limitations of the current literature hinder the possibility of drawing any solid conclusion, and more high-quality RCTs are needed. The protocol is registered at the Danish Health Authority website.


Asunto(s)
Trastorno del Espectro Autista/dietoterapia , Caseínas/administración & dosificación , Dieta Sin Gluten , Dieta con Restricción de Proteínas , Adolescente , Niño , Dieta Sin Gluten/efectos adversos , Dieta Sin Gluten/métodos , Dieta con Restricción de Proteínas/efectos adversos , Dieta con Restricción de Proteínas/métodos , Humanos
20.
J Dev Orig Health Dis ; 12(6): 915-922, 2021 12.
Artículo en Inglés | MEDLINE | ID: mdl-33353580

RESUMEN

Although abundant evidence exists that adverse events during pregnancy lead to chronic conditions, there is limited information on the impact of acute insults such as sepsis. This study tested the hypothesis that impaired fetal development leads to altered organ responses to a septic insult in both male and female adult offspring. Fetal growth restricted (FGR) rats were generated using a maternal protein-restricted diet. Male and female FGR and control diet rats were housed until 150-160 d of age when they were exposed either a saline (control) or a fecal slurry intraperitoneal (Sepsis) injection. After 6 h, livers and lungs were analyzed for inflammation and, additionally, the amounts and function of pulmonary surfactant were measured. The results showed increases in the steady-state mRNA levels of inflammatory cytokines in the liver in response to the septic insult in both males and females; these responses were not different between FGR and control diet groups. In the lungs, cytokines were not detectable in any of the experimental groups. A significant decrease in the relative amount of surfactant was observed in male FGR offspring, but this was not observed in control males or in female animals. Overall, it is concluded that FGR induced by maternal protein restriction does not impact liver and lung inflammatory response to sepsis in either male or female adult rats. An altered septic response in male FGR offspring with respect to surfactant may imply a contribution to lung dysfunction.


Asunto(s)
Dieta con Restricción de Proteínas/efectos adversos , Sepsis/fisiopatología , Fenómenos Fisiológicos Nutricionales de los Animales , Animales , Dieta con Restricción de Proteínas/métodos , Modelos Animales de Enfermedad , Quebec , Ratas , Ratas Wistar , Sepsis/dietoterapia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA